View Item 

Show simple item record

Antipsychotic‐Induced Hyperprolactinemia

dc.contributor.authorBostwick, Jolene R.en_US
dc.contributor.authorGuthrie, Sally K.en_US
dc.contributor.authorEllingrod, Vicki L.en_US
dc.date.accessioned2012-03-16T15:57:29Z
dc.date.available2012-03-16T15:57:29Z
dc.date.issued2009-01en_US
dc.identifier.citationBostwick, Jolene R.; Guthrie, Sally K.; Ellingrod, Vicki L. (2009). "Antipsychotic‐Induced Hyperprolactinemia." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(1). <http://hdl.handle.net/2027.42/90238>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90238
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherSexual Dysfunctionen_US
dc.subject.otherHyperprolactinemiaen_US
dc.subject.otherProlactinen_US
dc.subject.otherAntipsychoticsen_US
dc.subject.otherSchizophreniaen_US
dc.subject.otherOsteoporosisen_US
dc.subject.otherBreast Canceren_US
dc.subject.otherAmenorrheaen_US
dc.titleAntipsychotic‐Induced Hyperprolactinemiaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan (all authors).en_US
dc.identifier.pmid19113797en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90238/1/phco.29.1.64.pdf
dc.identifier.doi10.1592/phco.29.1.64en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceMeaney, A.M., Smith, S., Howes, O.D., O'Brien, M., Murray, R.M., O'Keane, V.. Effects of long‐term prolactin‐raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184: 503 – 8.en_US
dc.identifier.citedreferenceThangavelu, K., Geetanjali, S.. Menstrual disturbance and galactorrhea in people taking conventional antipsychotic medications. Exper Clin Psychopharmacol 2006; 14: 459 – 60.en_US
dc.identifier.citedreferenceLambert, M., Haro, J.M., Novick, D. et al. Olanzapine vs. other antipsychotics in actual out‐patient settings: six months tolerability results from the European schizophrenia out‐patient health outcomes study. Acta Psychiatr Scand 2005; 111: 232 – 43.en_US
dc.identifier.citedreferenceBobes, J., García‐Portilla, M.P., Rejas, J. et al. Frequency of sexual dysfunction and other reproductive side‐effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J Sex Marital Ther 2003; 29: 125 – 47.en_US
dc.identifier.citedreferenceKelly, D.L., Conley, R.R.. Sexuality and schizophrenia: a review. Schizophr Bull 2004; 30: 767 – 79.en_US
dc.identifier.citedreferenceKnegtering, H., van der Moolen, A.E., Castelein, S., Kluiter, H., van den Bosch, R.J.. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuro-endocrinology 2003; 28 ( suppl 2 ): 109 – 23.en_US
dc.identifier.citedreferenceRiecher‐Rossler, A.. Oestrogens and schizophrenia. Curr Opin Psychiatry 2003; 16: 187 – 92.en_US
dc.identifier.citedreferenceHuber, T.J., Rollnik, J., Wilhelms, J., von zur Mühlen, A., Emrich, H.M., Schneider, U.. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001; 26; 27 – 35.en_US
dc.identifier.citedreferenceLiu‐Seifert, H., Kinon, B.J., Ahl, J., Lamberson, S.. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin‐elevating antipsychotics. Ann N Y Acad Sci 2004; 1032: 297 – 8.en_US
dc.identifier.citedreferenceHoward, L., Kirkwood, G., Leese, M.. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007; 190: 129 – 34.en_US
dc.identifier.citedreferenceHankinson, S.E., Willett, W.C., Michaud, D.S. et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999; 91: 629 – 34.en_US
dc.identifier.citedreferenceTworoger, S.S., Hankinson, S.E.. Prolactin and breast cancer risk. Cancer Lett 2006; 243: 160 – 9.en_US
dc.identifier.citedreferenceWang, P.S., Walker, A.M., Tsuang, M.T. et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002; 59: 1147 – 54.en_US
dc.identifier.citedreferenceHalbreich, U., Shen, J., Panaro, V.. Are chronic psychiatric patients at increased risk for developing breast cancer?. Am J Psychiatry 1996; 153: 559 – 60.en_US
dc.identifier.citedreferenceSzarfman, A., Tonning, J.M., Levine, J.G., Doraiswamy, P.M.. Atypical antipsychotics and pituitary tumors: a pharmaco‐vigilance study. Pharmacotherapy 2006; 26: 748 – 58.en_US
dc.identifier.citedreferenceMarder, S.R., Essock, S.M., Miller, A.L. et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334 – 49.en_US
dc.identifier.citedreferenceWolf, J., Fiedler, U.. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 2007; 32: 197 – 8.en_US
dc.identifier.citedreferenceShim, J.C., Shin, J.G., Kelly, D.L. et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. Am J Psychiatry 2007; 164: 1404 – 10.en_US
dc.identifier.citedreferenceBankowski, B.J., Zacur, H.A.. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003; 46: 349 – 62.en_US
dc.identifier.citedreferenceNaidoo, U., Goff, D.C., Klibanski, A.. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28: 97 – 108.en_US
dc.identifier.citedreferencePerkins, D.O.. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63: 1121 – 8.en_US
dc.identifier.citedreferenceFleischhacker, W.W., Meise, U., Gunther, V., Kurz, M.. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatrica Scand 1994; 89 ( suppl 382 ): 11 – 15.en_US
dc.identifier.citedreferenceHalbreich, U.. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 2007; 21: 641 – 57.en_US
dc.identifier.citedreferenceMisra, M., Papakostas, G.I., Klibanski, A.. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65: 1607 – 18.en_US
dc.identifier.citedreferenceLehman, D., Meyer, J.M.. Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2005; 76: 131 – 3.en_US
dc.identifier.citedreferenceHaddad, P.M., Wieck, A.. Antipsychotic‐induced hyper‐prolactinemia: mechanisms, clinical features, and management. Drugs 2004; 64: 2291 – 314.en_US
dc.identifier.citedreferenceBen‐Jonathan, N., Hugo, E.R., Brandebourg, T.D., LaPensee, C.R.. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17: 110 – 16.en_US
dc.identifier.citedreferenceHarris, J., Stanford, P.M., Oakes, S.R., Ormandy, C.J.. Prolactin and prolactin receptor: new targets of an old hormone. Ann Med 2004; 36: 414 – 25.en_US
dc.identifier.citedreferenceParker, K.L., Schimmer, B.P.. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton, L.L., Lazo, J.S., Parker, K.L., eds. Goodman & Gilman's the pharmacologic basis of therapeutics, 11th ed. New York: McGraw‐Hill Companies, Inc., 2006: 1489 – 510.en_US
dc.identifier.citedreferenceYoung, R.M., Lawford, B.R., Barnes, M. et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185: 147 – 51.en_US
dc.identifier.citedreferenceThompson, J., Thomas, N., Singleton, A. et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479 – 84.en_US
dc.identifier.citedreferenceNordström, A.L., Farde, L.. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug‐treated patients. J Clin Psychopharmacol 1998; 18: 305 – 10.en_US
dc.identifier.citedreferenceMihara, K., Kondo, T., Suzuki, A. et al. Prolactin response to nemonapride, a selective antagonist for D2, like dopamine receptors, in schizophrenic patients in relation to Taq 1 A polymorphism of DRD2 gene. Psychopharmacology 2000; 149: 246 – 50.en_US
dc.identifier.citedreferenceMolitch, M.E.. Medication‐induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050 – 7.en_US
dc.identifier.citedreferenceMelmed, S., Jameson, J.L.. Disorders of the anterior pituitary and hypothalamus. In: Kasper, D.L., Fauci, A.S., Longo, D.L., Braunwald, E., Hauser, S.L., Jameson, J.L., eds. Harrison's principles of internal medicine, 16th ed. New York: McGraw‐Hill Companies, Inc., 2005: 2076 – 97.en_US
dc.identifier.citedreferenceByerly, M., Suppes, T., Tran, Q., Baker, R.A.. Clinical implications of antipsychotic‐induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007; 27: 639 – 61.en_US
dc.identifier.citedreferenceKinon, B.J., Gilmore, J.A., Liu, H., Halbreich, U.M.. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28: 55 – 68.en_US
dc.identifier.citedreferenceMaguire, G.A.. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63 ( suppl 4 ): 56 – 62.en_US
dc.identifier.citedreferenceCrismon, M.L., Buckley, P.F.. Schizophrenia. In: DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., eds. Pharmacotherapy a pathophysiologic approach, 6th ed. New York: McGraw‐Hill Companies, Inc., 2005; 1209 – 33.en_US
dc.identifier.citedreferenceHalbreich, U., Kinon, B.J., Gilmore, J.A., Kahn, L.S.. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse events. Psychoneuroendocrinology 2003; 28: 53 – 67.en_US
dc.identifier.citedreferenceMeyer, J.M., Lehman, D.. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006; 18: 43 – 8.en_US
dc.identifier.citedreferenceHummer, M., Malik, P., Gasser, R.W. et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162: 162 – 7.en_US
dc.identifier.citedreferenceMeaney, A.M., O'Keane, V.. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007; 93: 136 – 43.en_US
dc.identifier.citedreferenceWelsch, C.W., Nagasawa, H.. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 1977; 37: 951 – 63.en_US
dc.identifier.citedreferencePalmer, J., Maurer, L.H.. Prolactin and breast cancer [letter]. Lancet 1972; 2: 1036.en_US
dc.identifier.citedreferenceMinton, J.P.. Prolactin and human breast cancer. Am J Surg 1974; 128: 628 – 30.en_US
dc.identifier.citedreferenceJanssen Pharmaceutica Products, L.P.. Risperdal (risperidone) package insert. Titusville, NJ; 2007.en_US
dc.identifier.citedreferenceKnegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggeman, R., van den Bosch, R.J.. Predominate role of the 9‐hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162: 1010 – 12.en_US
dc.identifier.citedreferenceRosenheck, R.A., Leslie, D.L., Sindelar, J., et al. Cost‐effectiveness of second‐generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080 – 9.en_US
dc.identifier.citedreferenceKuruvilla, A., Peedicayil, J., Srikrishna, G., Kuruvilla, K., Kanagasabapathy, A.S.. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharm Physiol 1992; 19: 603 – 6.en_US
dc.identifier.citedreferenceSmith, S., Wheeler, M.J., Murray, R., O'Keane, V.. The effects of antipsychotic‐induced hyperprolactinaemia on the hypothalamic‐pituitary‐gonadal axis. J Clin Psychopharmacol 2002; 22: 109 – 14.en_US
dc.identifier.citedreferenceKim, K.S., Pae, C.U., Chae, J.H. et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63: 408 – 13.en_US
dc.identifier.citedreferenceKane, J., Canas, F., Kramer, M. et al. Treatment of schizophrenia with paliperidone extended‐release tablets: a 6‐week placebo‐controlled trial. Schizophr Res 2007; 90: 147 – 61.en_US
dc.identifier.citedreferenceCrawford, A.M.K., Beasley, C.M., Tollefson, G.D.. The acute and long‐term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997; 26: 41 – 54.en_US
dc.identifier.citedreferenceBergemann, N., Mundt, C., Parzer, P. et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr Res 2005; 73: 357 – 66.en_US
dc.identifier.citedreferenceWeiden, P.J., Daniel, D.G., Simpson, G., Romano, S.J.. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23: 595 – 600.en_US
dc.identifier.citedreferenceArvanitis, L.A., Miller BG, for the Seroquel Trial 13 Study Group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233 – 46.en_US
dc.identifier.citedreferenceKane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763 – 71.en_US
dc.identifier.citedreferenceHaddad, P.M., Sharma, S.G.. Adverse effects of atypical antipsychotics differential risk and clinical implications. CNS Drugs 2007; 21: 911 – 36.en_US
dc.identifier.citedreferenceZito, J.M., Safer, D.J., dosReis, S. et al. Psychotropic practice patterns for youth: a 10‐year perspective. Arch Pediatr Adolesc Med 2003; 157: 17 – 25.en_US
dc.identifier.citedreferenceZito, J.M., Safer, D.J., Valluri, S., Gardner, J.F., Korelitz, J.J., Mattison, D.R.. Psychotherapeutic medication prevalence in Medicaid‐insured preschoolers. J Child Adolesc Psychopharmacol 2007; 17: 195 – 203.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.29.1.64.pdf
Size:
107.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.